The Potential Diagnostic and Prognostic Value of Circulating Micrornas in the Assessment of Patients With Prostate Cancer: Rational and Progress Publisher



Samami E¹ ; Pourali G^{2, 3} ; Arabpour M³ ; Fanipakdel A² ; Shahidsales S² ; Javadinia SA⁴ ; Hassanian SM³ ; Mohammadparast S⁵ ; Avan A^{3, 6} Show Affiliations
Source: Frontiers in Oncology Published:2022

Abstract

Prostate cancer (P.C.) is one of the most frequent diagnosed cancers among men and the first leading cause of death with an annual incidence of 1.4 million worldwide. Prostate-specific antigen is being used for screening/diagnosis of prostate disease, although it is associated with several limitations. Thus, identification of novel biomarkers is warranted for diagnosis of patients at earlier stages. MicroRNAs (miRNAs) are recently being emerged as potential biomarkers. It has been shown that these small molecules can be circulated in body fluids and prognosticate the risk of developing P.C. Several miRNAs, including MiR-20a, MiR-21, miR-375, miR-378, and miR-141, have been proposed to be expressed in prostate cancer. This review summarizes the current knowledge about possible molecular mechanisms and potential application of tissue specific and circulating microRNAs as diagnosis, prognosis, and therapeutic targets in prostate cancer. © 2022 Samami, Pourali, Arabpour, Fanipakdel, Shahidsales, Javadinia, Hassanian, Mohammadparast and Avan.